INTRODUCTION
Members of the nucleotide binding domain and leucine-rich repeat-containing (NLR, also known as NOD-like receptor) family are evolutionarily conserved components of the immune system that are key mediators of immune defense and inflammation (Takeuchi and Akira, 2010) . The major focus in the NLR field is on the inflammasome NLRs, which activate caspase-1 resulting in production of interleukin 1b (IL-1b) and interleukin 18 (IL-18). A subgroup of NLRs play an important role in the regulation of signaling pathways crucial for cell proliferation, survival, cellular differentiation, adhesion, migration, and metabolism, such as mitogen-activated protein kinases (MAPK) and nuclear factor kB (NF-kB) (Hayden and Ghosh, 2011; Sebolt-Leopold and Herrera, 2004; Wullaert et al., 2011) . Aberrant activation of these pathways initiate and promote tumor development (Elinav et al., 2013) ; thus, it is important to determine if NLRs control these pathways during tumorigenesis and if these findings have translational relevance in human cancers.
Colorectal cancer (CRC) is the third most common cancer in both men and women and the second leading cause of cancerrelated mortality in the United States with estimates of over 130,000 new cases diagnosed and 50,000 deaths in 2013 (Siegel et al., 2013) . Recent studies reported an increased frequency of colon cancer in adults younger than 50, with these patients more likely to show an advance stage of the disease (Bailey et al., 2015) . Over 90% of CRCs are adenocarcinomas, while rarer forms include neuroendocrine, squamous cell, spindle cell, and undifferentiated carcinomas (Fleming et al., 2012) .
Colitis-associated colon cancer (CAC) accounts for 1% of CRC (Yashiro, 2014) . The link between chronic inflammation and increased tumorigenesis has been well documented in inflammatory bowel diseases (IBD), including ulcerative colitis (UC), and Crohn's disease (CD) (Rogler, 2014; Terzi c et al., 2010) . IBD are associated with increased production of pro-inflammatory cytokines, which are associated with the activation of NF-kB, signal transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase (MAPK) . Each of these pathways contributes to tumor progression in CRC (Ben-Neriah and Karin, 2011; Dhillon et al., 2007; O'Shea et al., 2013) . NF-kB regulation of CRC development occurs through the enhanced survival of pre-malignant epithelial cells and release of inflammatory cytokines, which promote tumor growth (Ditsworth and Zong, 2004; Greten et al., 2004; Staudt, 2010) . Elevated levels of IL-1b, tumor necrosis factor a (TNF-a), and interleukin 6 (IL-6) are commonly associated with both IBD and CRC (Becker et al., 2005; Lin and Karin, 2007; Waldner et al., 2012) . In particular, IL-6 and STAT3 potently stimulate colon cancer proliferation and have critical roles in colon tumor development in preclinical models (Bollrath et al., 2009; Corvinus et al., 2005; Grivennikov et al., 2009) . There is also a strong correlation between local IL-6 accumulation and clinical activity of IBD in humans (Atreya and Neurath, 2005; Hyams et al., 1993) .
The initial connection between IBD and the NLR family was based on the strong genetic association between NOD2/ CARD15 mutations in Crohn's disease and colon cancer (Hugot et al., 2001; Kurzawski et al., 2004; Ogura et al., 2001 ). Mouse models of CAC have demonstrated that other NLRs, such as NLRP3, NLRP6, and NLRP12, also protect against CAC Anand et al., 2012; Chen et al., 2011; Dupaul-Chicoine et al., 2010; Elinav et al., 2011; Zaki et al., 2010) . The NLRP3 and NLRP6 inflammasomes appear to limit CAC primarily through the induction of IL-18, while NLRP12 reduces NF-kB and ERK activation, hence reducing chemokines and nitric oxide that promote tumorigenesis (Allen et al., 2012; Zaki et al., 2011) .
NLRX1 does not exhibit inflammasome function and is uniquely localized to the mitochondria (Moore et al., 2008; Tattoli et al., 2008) . NLRX1 attenuates TRAF6, mitochondrial antiviral signaling protein (MAVS)/retinoic acid-inducible gene I (RIG-I), interferon regulatory factor 3 (IRF3), and IkB kinase (IKK) signaling in response to viral infection and TLR signaling (Allen et al., 2011; Moore et al., 2008; Xia et al., 2011) , but it is also required for the induction of reactive oxygen species in response to pathogens (Abdul-Sater et al., 2010; Tattoli et al., 2008) . As a result of its impact on key signaling pathways, NLRX1 negatively regulates the expression of pro-inflammatory cytokines, including IL-6 (Allen et al., 2011) , a cytokine that has a central role in CAC and is a target of therapies for the treatment of IBD (Allocca et al., 2013) . A recent study reported that NLRX1 expression is reduced in patients with chronic obstructive pulmonary disease (COPD), and the absence of NLRX1 exacerbated a model of COPD (Kang et al., 2015) . Thus, one of the functions of NLRX1 is to attenuate over-zealous immune responses. Therefore, elucidating the molecular regulation and function of NLRX1 in CAC or sporadic CRC has the potential to identify novel pathways and therapeutic targets for the treatment of colon cancer.
Analyses of inflammasome NLRs in models of CAC have been well reported; however, CAC represents only 1% of CRC. By contrast, the importance of NLRs in the more prevalent sporadic colon tumors is sorely lacking. This current study identifies an important role for Nlrx1 in suppressing tumorigenesis in both CAC and sporadic colon cancer models by restricting the activation of NF-kB, MAPK, STAT3, and IL-6 production. In contrast to most inflammasome NLRs, which function through the myeloidmonocytic hematopoietic system, NLRX1 exerts its impact primarily through non-hematopoietic cells such as colon crypt cells. The importance of NLRX1 in cells other than hematopoietic is consistent with its role in sporadic CRC modeled after familial adenomatous polyposis (FAP). FAP is a hereditary disease characterized by the development of colon polyps, attributed to the deletion of the APC (adenomatous polyposis coli) gene (Fodde et al., 2001 activation, decreased tumor number, and increased survival, indicating that increased IL-6 is a causative factor in tumorigenesis linked to NLRX1-deficiency. Expression analyses of clinical human colon cancer samples and meta-analysis of multiple public databases revealed that NLRX1 expression is significantly lowered in CRC when compared to normal colon tissues. These findings indicate that the loss or reduction of NLRX1 may contribute to human colon cancers.
RESULTS

Nlrx1
À/À Mice Are More Susceptible to Chronic Azoxymethane/Dextran Sodium Sulfate-Induced Colitis-Associated Colon Cancer To test the hypothesis that NLRX1 impacts colon tumorigenesis, Nlrx1 À/À and wild-type (WT) littermates were subjected to a wellcharacterized CAC model that combines the genotoxic DNAmethylation agent, azoxymethane (AOM), and dextran sodium sulfate (DSS) . CAC was induced by injecting a single dose of AOM, followed by three cycles of 3% DSS administration for 5 days followed by 14 days of regular drinking water, hereafter referred to as A/D treatment ( Figure 1A) . A/Dtreated Nlrx1 À/À mice exhibited statistically greater weight loss than A/D-treated wild-type mice ( Figure 1B (K) Densitometric measurement of western blots was obtained from three independent experiments. n R 5 mice/group, n.s., non-significant. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. See also Figure S1 .
and the presence of blood in the stool was significantly higher in Nlrx1 À/À animals compared to WT controls ( Figure 1C ). The histologic appearance of the Nlrx1 À/À colons harvested at 55 days post A/D injection showed increased total histology score (THS) ( Figures 1D and 1E ), which evaluates severity and extent of inflammation, epithelial defects, crypt atrophy, and mucosal dysplasia/neoplasia. Nlrx1 À/À -treated colons had more widespread epithelial defects compared to controls as scored in a blinded fashion by a board-certified veterinarian pathologist ( Figure 1F , see legend for a detailed description). On day 55 after the start of A/D, colons were harvested and macroscopic polyps were counted. A/D-treated Nlrx1 À/À mice exhibited significantly more polyps in the distal region of their colons compared to A/D-treated WT controls ( Figure 1G ). Nlrx1
À/À mice also exhibited greater tumor volume compared to WT controls ( Figure S1A ). Mice treated with DSS or AOM alone had few, if any, polyps. Further analysis by endoscopy with a different group of mice revealed that A/D-treated Nlrx1 À/À mice developed more polyps or lesions at the time of examination (day 48 of the A/D treatment course) compared to WT control mice (Figure S1B) . NLRX1 attenuates cytokine expression in fibroblasts (Allen et al., 2011) . To assess if this occurs in CAC, serum from A/D-treated Nlrx1 À/À mice were prepared and showed significantly higher levels of IL-6, TNF-a, and IL-1b protein than controls as determined by ELISA ( Figure 1H ) and greater Il6, Tnfa, and Il1b RNA expression as determined by real-time PCR from colon tissues ( Figure 1I ). Previous reports have demonstrated the role of increased NF-kB and ERK activation in CAC development (Greten et al., 2004) . Western blot analysis revealed that colons of chronic DSS-or A/D-treated Nlrx1 À/À mice had higher levels of phosphorylated IkBa and ERK1/2 compared to WT controls ( Figures 1J and 1K ). Furthermore, IL-6 induces the activation of STAT3, which is dysregulated in colon cancer. Colons from A/D-treated Nlrx1 À/À mice had significantly higher levels of phosphorylated STAT3 compared to WT controls ( Figures  1J and 1K ). These results show that NLRX1 mitigates several known tumor-promoting signaling pathways during CAC.
Nlrx1 Expression in the Non-hematopoietic Compartment Mediates Protection against Colon Tumorigenesis NLRX1 is widely expressed in different tissues and organs (Moore et al., 2008) , hence its impact on CAC might be attributed to its expression in hematopoietic and/or non-hematopoietic cells. To address this, the following four groups of bone marrow chimeras were generated to test whether hematopoietic and/or non-hematopoietic cells were needed to protect against polyp formation: (1) irradiated WT mice that received bone marrow from WT littermates (WT > WT, control group), (2) irradiated WT control mice that received bone marrow from Nlrx1 À/À do-
, global Nlrx1 deficiency), and (4) Figures 2C and 2D ). Nlrx1 À/À > Nlrx1 À/À had a higher THS possibly due to the fact that NRLX1 is expressed in many different cell types ( Figure 2D ). Similar to findings with nonchimeric Nlrx1 À/À mice, the Nlrx1 À/À > Nlrx1 À/À group had a higher number of colonic polyps than WT > WT controls (Figure 2E) . WT > Nlrx1 À/À mice showed significantly higher numbers of polyps than the WT > WT and Nlrx1 À/À > WT mice ( Figure 2E ).
Colonic polyp numbers in Nlrx1 À/À > WT mice were not signifi-
and WT > Nlrx1 À/À mice, but not Nlrx1 À/À > WT mice, had significantly increased tumor volume compared to WT > WT mice (Figure 2F) . Additionally, phosphorylated STAT3 was higher in
À/À > WT and WT > WT mice ( Figure 2G ). A composite of three experiments confirmed these results ( Figure 2H ). These results indicate that the presence of Nlrx1 in the non-hematopoietic compartment is primarily required to limit A/D-induced tumorigenesis and STAT3 activation.
Loss of Nlrx1 in the Apc min/+ Model of Sporadic CRC
Leads to Increased Mortality and Tumor Burden
The above data indicate a contribution of Nlrx1-deficiency from the non-hematopoietic compartment during CAC pathogenesis. However, the majority of colon cancers are not associated with CAC. Therefore, we explored the role of NLRX1 in a model of sporadic colon cancer. APC mutations are found in $85% of human colon cancers or precancerous adenomas, and the loss of APC in epithelial cells is sufficient to drive intestinal tumorigenesis (Kinzler and Vogelstein, 1996; Schwitalla et al., 2013) . Apc min/+ mice have a germline mutation in the APC gene and develop spontaneous polyps (Fodde et al., 2001) . Usually, Apc min/+ mice become moribund within 168 days of age due to complications from intestinal tumors (Heyer et al., 1999 Figure 3A ).
Mice were monitored and harvested at 42, 84, and 168 days of age to elucidate potential factors of early mortality ( Figure S2A ). At 168 days, Nlrx1 and 168 days of age. Each data point represents one animal. n R 5 mice/group, n.s., non-significant. *p < 0.05, **p < 0.01, and ****p < 0.0001. See also Figure S2 . Figure 4A , see figure legend for a detailed description of the histology). We also observed a higher rate of distal inflammation in the colons of Nlrx1 À/À Apc min/+ mice ( Figure 4B ). In addition, we observed no difference in the percentage of cleaved caspase 3, a marker of apoptosis, between WT and Nlrx1 À/À ( Figure 4C ) while we saw significantly higher levels of Ki67 + cells in the basal end of colon crypts in Nlrx1
and Nlrx1 À/À Apc min/+ mice compared to wild-type and Apc min/+ mice, which is an indicator of increased proliferation ( Figures  4D and 4E) . APC controls the stability of b-catenin, a key regulator of Wnt signaling, stem cell renewal, cell fate, and growth (Clevers and Nusse, 2012) . Additionally, increased cytoplasmic b-catenin is a marker of carcinogenesis (Fodde et al., 2001 Figure 4F ). Our findings indicate that STAT3 was hyperactivated in the absence of NLRX1 ( Figure 1J ). STAT3 is known to activate cathepsin-B, which is involved in the oncogenesis and metastasis of human cancers and it is upregulated in dysplastic adenomas and colorectal carcinoma Kuester et al., 2008) . Ex vivo imaging of colons of Nlrx1
, and WT controls injected with a cathepsin B-inducible fluorescence probe (Prosense 680) Gounaris et al., 2013) Figure 4D ), we isolated these cells to determine the impact of NLRX1-deficiency. These cells were EpCAM hi and CD45 lo ( Figure S3 ). Nlrx1
Apc min/+ colon crypts from 84-day-old mice had higher levels of phosphorylated p65, ERK1/2, and STAT3 ( Figure 5C ) than controls. Since STAT3 can be activated by the key tumor-promoting cytokine, IL-6, Il6 transcript was measured by qPCR, and it was significantly increased in Nlrx1 Figure 5D ). In contrast, levels of Tnfa and Il1b were not significantly different between Apc min/+ and Nlrx1 Figure 5D ). ELISA analysis verified significantly higher levels of IL-6 protein produced by colonic samples isolated from Nlrx1
Apc min/+ animals compared to Apc min/+ mice, but no difference in IL-1b and TNF-a, which was below detection ( Figure 5E ). Taken together, these results indicate that the loss of NLRX1-activated multiple pathways that contribute to tumor development or progression.
Anti-IL6R Therapy Significantly Decreases Tumor
Burden and STAT3 Activity in the Nlrx1
To assess whether the pathways delineated above contributed to the mechanism by which NLRX1 suppressed tumor growth, we directly assessed the role of elevated IL-6 in Nlrx1 Figure 6E ). STAT3 is well documented to regulate the initial events of tumor development, progression, and invasiveness (Waldner et al., 2012 ) ( Figure 6F ) and decreased levels of phosphorylated STAT3 observed in anti-IL6R-treated Nlrx1 À/À Apc min/+ animals correlated positively with decreased polyp numbers ( Figures 6D and 6F) . Thus, these results indicate that increased IL-6 found in Nlrx1
played a causative role in increased polyp formation and heightened STAT3 activation.
NLRX1 Expression Is Reduced in Colorectal Cancer Based on Analysis of the Oncomine Platform and Newly Isolated Clinical Samples
To examine the relevance of the data in preclinical models to human colon cancer, the levels of NLRX1 expression in human CRC was subjected to bioinformatics mining using the (B) Total Histology score and distal colon inflammation were determined in H&E-stained colon sections represented in A. All slides were scored in a blinded fashion.
(legend continued on next page)
Please org/10.1016/j.celrep.2016.02.064 Oncomine Platform database. This was followed by an examination of newly isolated clinical samples from a Chinese Cohort. Oncomine Platform is an online assembly of microarrays. We analyzed five databases (listed in the Experimental Procedures) that contained information regarding NLRX1 expression. We first analyzed the Cancer Genome Atlas (TCGA) database, which is the most comprehensive set containing 215 patient and 22 control samples (Cancer Genome Atlas, 2012) . This database showed that the expression of NLRX1 transcript was significantly decreased in colorectal cancer ( Figure 7A ). Next, we evaluated the expression levels of NLRX1 transcript at various (E) IL-6, TNF-a, and IL-1b proteins produced by colon explants were analyzed by ELISA, n R 3 mice/group. n.s., non-significant. *p < 0.05, ***p < 0.001, and ****p < 0.0001. See also Figure S3 .
(C-E) Quantification of positive cleaved caspase-3 (C) or Ki-67 (D) cells stained per half-length of crypt was determined from age-matched Apc min/+ and
Nlrx1
À/À
Apc min/+ mice at 168 days of age shown in (E) for Ki-67. n R 4 mice/group, n.s., non-significant. *p < 0.05 **p < 0.01, ***p < 0.001, and ****p < 0.0001. Scale bars represent 100 mm. stages of cancer progression using the TCGA database ( Figure 7B ). CRC cases were staged according to the staging system determined by the American Joint Committee on Cancer (AJCC) and also known as the tumor-node-metastasis (TNM) system. In stage I, the tumor has spread beyond the inner lining of the colon to the second and third layers of the colon. In stage II, the tumor has spread to the muscle wall of the colon. In stage III, the cancer has metastasized to lymph nodes. In stage IV, the cancer has metastasized to secondary areas of the body such as the liver or lung. This analysis shows that NLRX1 expression was significantly higher in healthy controls versus all four CRC stages ( Figure 7B ). Next, we confirmed these findings using four smaller databases within the Oncomine Platform. Significantly lower expression of NLRX1 was detected in CRC samples in all four databases ( Figure 7C) . Thus, the composite data from five public databases support the conclusion that NLRX1 expression is statistically lower in CRC than in healthy colons.
Public database typically do not provide detailed information regarding the patients. Thus, we analyzed mRNA isolated from 40 formalin-fixed and paraffin-embedded (FFPE) CRC samples plus 40 adjacent normal tissues obtained from a Chinese patient Each data point represents one animal. n R 4 mice/group, n.s., non-significant. *p < 0.05 **p < 0.01, ***p < 0.001, and ****p < 0.0001. cohort for the expression of NLRX1. The patients selected had not received any chemotherapy or radiotherapy prior to colonic resection. In agreement with Figure 7A , NLRX1 transcripts were significantly reduced within the CRC samples relative to healthy tissues ( Figure 7D ). The combined data collected from multiple public databases and an additional cohort of human clinical samples provides overwhelming clinical evidence that NLRX1 gene expression is reduced in human CRC in comparison to healthy colons, further indicating a critical role for NLRX1 in limiting CRC.
(legend continued on next page)
DISCUSSION
The link between cancer and a number of key signaling pathways is well established (Coussens and Werb, 2002) . Elevated NF-kB signaling can de-differentiate intestinal epithelial cells that eventually acquire stem-like properties and tumor-initiating capacity (Shaked et al., 2012) . NF-kB also facilitates Wnt-driven proliferation of intestinal stem cells, which leads to CRC (Myant et al., 2013; Schwitalla et al., 2013) . MAPK regulates intestinal cell proliferation and epithelial differentiation and promotes progression and oncogenesis of human CRC (Dhillon et al., 2007; Lee et al., 2010; Taupin and Podolsky, 1999) . NF-kB and STAT3 cooperatively regulate a number of target genes regulating cell cycle and proliferation (Lee et al., 2009; Yang et al., 2007) . This work shows that NLRX1 serves as a checkpoint of these multiple critical cancer-promoting pathways to maintain a homeostatic, noncancerous state. A previous study of NLRX1 in a model that used AOM alone, which is not known to strongly induce tumorigenesis, and a model that involved a short course (3-day) of AOM-DSS treatment, which is unlikely to induce full tumorigenesis, has resulted in conflicting findings regarding the role of NLRX1 (Soares et al., 2014) . In contrast, the current study is distinguished by several unique features First, NLRX1 uniformly suppressed colon tumorigenesis in both CAC and sporadic colon cancer models. Second, the loss of Nlrx1 expression led to heightened IL-6 production and activated STAT3, which are key regulatory pathways in colon cancer that have not been connected to NLR function in tumors. Enhanced NF-kB and ERK activity are known to enhance levels of IL-6, which can lead to STAT3 activation resulting in increased oncogenesis (Corvinus et al., 2005) . Cross talk between STAT3 and b-catenin have been documented in different cancers (Armanious et al., 2010; Ibrahem et al., 2014) , and STAT3 can also enhance cathepsin B (Dauer et al., 2005) , which enhances cancer progression and cell proliferation. Since cathepsin B and b-catenin activity are heightened in Nlrx1 À/À Apc min/+ mice, inhibitors of these two proteins may be useful in targeting human CRCs with low NLRX1 expression. Third, while other NLRs such as NLRP3 exert their impact primarily through the hematopoietic compartment, NLRX1 exerts its impact on tumorigenesis mostly via the non-hematopoietic compartment such as colon crypts. Fourth, anti-IL6R therapy effectively decreased tumorigenesis and STAT3 activation in Nlrx1 À/À Apc min/+ animals. Finally, NLRX1 is also reduced in multiple human CRC patient cohorts, which confers translational relevance to these findings and supports the concept that NLRX1 may serve as a checkpoint against human colon cancer. The discovery of reduced NLRX1 in human CRC further suggests that NLRX1 expression may be used as a biomarker of CAC or CRC (Thorsteinsdottir et al., 2011) . This finding also has implications for personalized therapy. For example, inhibitors of STAT3 or IL-6, which are Food and Drug Administration (FDA)-approved for other diseases, might be repurposed for controlling human CRCs that have low NLRX1 expression. Based on the findings in this and previous reports, a working model of how NLRX1 affects tumorigenesis is shown in Figure 6F . In summary, this report finds that the presence of NLRX1 limits activation of key signaling pathways leading to NF-kB, MAPK, IL-6, and STAT3 activation, which promote various aspects of tumor development. The loss of NLRX1 creates a microenvironment that potentiates the development of tumors in both colitisassociated and sporadic models of CRC. A possible impact is that NLRX1 affects tumor-promoting signals via changes in the microbiome, which would be an important future investigation.
EXPERIMENTAL PROCEDURES Animals
All studies were conducted in accordance with IACUC guidelines of the University of North Carolina (UNC) at Chapel Hill and NIH guide for the Care and Use of Laboratory Animals. All experiments were performed under SPF conditions using either 6-or 8-week-old male mice or with age as indicated. C57BL/6 (wild-type mice) and Apc min/+ mice originated from Jackson Laboratories and were maintained at UNC Chapel Hill for more than nine generations. Nlrx1 À/À mice on the C57BL/6 background have been described previously (Moore et al., 2008 
Assays
Isolation of RNA, tissue extracts, and soluble protein and biochemical and molecular analyses and molecular imaging of proteases are described in the Supplemental Experimental Procedures.
Bioinformatics and Experimental Analysis of NLRX1 Expression in Human CRC
Microarray studies from the Oncomine Platform containing data describing NLRX1 expression in CRC and the collection and processing of human CRC specimens are described in the Supplemental Experimental Procedures.
Statistics
All results are presented as the mean ± SEM. Significance between two groups was assessed by the Student's two-tailed t test. Datasets that had more than two sets of data for analysis were analyzed by ANOVA with Tukey-Kramer HSD post test for multiple comparisons to determine significance. The product limit method of Kaplan-Meier was utilized for generating the survival curves, which were compared using the log rank test. See the (E) Protein lysates were isolated from distal colon tissues obtained from WT, Nlrx1 ) (mean ± SEM). **p < 0.01, ***p < 0.001, and ****p < 0.0001. populations were determine to be < 0.4%.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES:
Animals: All experiments were performed under specific-pathogen-free (SPF)
conditions. Sentinel mice were routinely monitored for bacterial, viral, ecto, and endoparasitic pathogens so to confirm SPF condition. For littermates, heterozygous mice were breed and maintained for experimental work.
Induction of experimental chronic colitis and colitis-associated colon cancer (CAC):
To induce chronic colitis, littermates were given three cycles of 3% DSS for 5 days followed by 14 days of regular drinking water . To Induce CAC, animals were given a single i.p. injection of the mutagen azoxymethane (AOM, 10 mg/kg body weight) (Sigma-Aldrich) in combination with three cycles of 3% DSS in drinking water for 5 days followed by regular drinking water for 14 days. Animals were euthanized at the end of the study on day 55 or when moribund with weight loss greater than 20% as stated in our IACUCapproved protocol. Animals were monitored for weight loss daily during DSS treatment and once every two days during regular water administration to measure disease progression. Furthermore, clinical score assessments were blindly performed after each round of DSS at days 7, 26, and 45, which consisted assessments of body condition, stool consistency, rectal bleeding and presence of stool blood measured using Hemoccult Immunochemical Fecal Occult (Beckman Coulter) as previously described . Tumor volumes were determined as the average sum of the volumes [V = (width 2 x length)/2] of all colon tumors per mouse.
Radiation bone marrow chimeras:
Radiation bone marrow chimeric mice were generated as previously described given 2 mg/ml neomycin in drinking water for 14 days and housed for an additional 56 days to allow for full bone marrow reconstitution before administration of AOM/DSS.
Molecular imaging of proteases:
To quantify cathepsin B activity, an indirect imaging approach using a cathepsin B-catalyzable fluorescent target as described previously Ding et al., 2012) was utilized.
Specifically, the Near Infrared Fluorescence imaging probe ProSense 680 (PerkinElmer, Cat# NEV10003) emits a signal when activated by proteases with the highest specificity demonstrated by cathepsin B (Jaffer et al., 2008) and has been used for intestinal tumor detection (Zhang et al., 2008) . formalin and embedded in paraffin. Hematoxylin and eosin (H&E) staining was performed on 5-micron-thick sections, and hyperplasia and dysplasia were blindly evaluated by a Board-certified veterinary pathologist. Briefly, individual lesions were scored as described previously (Meira et al., 2008) , and a total histology score for each specimen was completed by summing the individual lesion scores. Additional sections were stained for the tumorigenesis marker β- Isolation of colon crypts: Following a previously described protocol (Fuller et al., 2013) , colons were removed and flushed with cold PBS. Colons were cut into 2-3 cm pieces and transferred to 3mM EDTA/1.5mM DTT in PBS and place on ice for 30 minutes. After manual shaking for 30 seconds, the tissue is moved to fresh cold PBS with 3 mM EDTA and placed at 37°C for 10 minutes. Samples were shaken vigorously for 1 minute to separate the colon crypts from the submucosa. The submucosa was discarded, the samples were spun at 300 x g for 5 minutes and the pellet was frozen for protein preparation. Anti-IL-6R Antibody Treatment of Mice: IL-6 blockade was achieved using an intraperitoneal injection of 20 µg/mL of Tocilizumab (Genentech) every two weeks for 10 weeks. Animals of 6 weeks of age were monitored weekly for weight changed and body condition after initiation of antibody treatment.
Bioinformatics analysis of NLRX1 expression in human CRC: Microarray studies containing data that focused on the expression of NLRX1 in CRC were obtained using the gene search function of the Oncomine ® Platform (www.oncomine.org). The default parameters set by the platform were used:
threshold fold change was greater or equal to 1.5X, p value was greater or equal to 0.0001 and the gene rank was in the top 10%. Data analysis was expressed as fold change of expression in CRC compared to normal tissues (Wang et al., 2014 (Graudens et al., 2006) . Following an analysis of NLRX1 expression, the results from these databases were sorted based on the p value, and the log-transformed median centered raw data were downloaded from the Oncomine® Platform. Graph Pad software was used to create the boxplots and dot figures.
Collection of clinical CRC specimens: Bio-specimens were collected from 40 patients newly diagnosed with colon or rectum adenocarcinoma as previously described (Liu et al., 2015) . These patients underwent surgical resection during 
RNA extraction from FFPE tissues and quantitative real-time PCR:
RecoverAll TM Total Nucleic Acid Isolation Kit was used to isolate RNA from FFPE tissues according to the manufacturer's protocol (AM1975, Ambion Austin, TX).
Briefly, 1 ml of 100% xylene was added to 3 pieces of 20 mm thick FFPE sections. Samples were incubated for 3 min at 50°C to remove traces of paraffin and centrifuged for 2 min to remove the xylene. Pellets were washed twice with 1 ml of 100% ethanol, digested with 200 µl of proteinase K digestive buffer at 50°C
overnight and then incubated with DNase I. Samples were washed, total RNA was eluted with distilled water and the RNA concentration of each sample was determined by a Nanodrop 2000 spectrophotometer. IScript™ cDNA Synthesis
Kit was used to generate cDNA and Q-PCR was performed for human NLRX1 (Hs00226360_m1), GAPDH (Hs02758991_g1), ACTB (Hs01060665_g1) and 18S rRNA (Hs03928985_g1). All samples were analyzed in triplicate. Relative mRNA expression levels were determined by the 2 -ΔΔCT or log-transformed method. Differences between two sample groups were analyzed using the paired or unpaired Student's t-test (Mann-Whitney unpaired test or Wilcoxon matchedpairs signed test). The association between gene expression levels and clinical parameters was performed by the analysis of variance (ANOVA). A p value that is <0.05 is considered statistically significant. All statistical analysis was performed using the Graph pad Prism software.
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